Open AccessConcise Review: Is Cardiac Cell Therapy Dead? Embarrassing Trial Outcomes and New Directions for the Future
Author(s) -
Tang JunNan,
Cores Jhon,
Huang Ke,
Cui XiaoLin,
Luo Lan,
Zhang JinYing,
Li TaoSheng,
Qian Li,
Cheng Ke
Publication year - 2018
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.1002/sctm.17-0196
Subject(s) - stem cell therapy , cell therapy , stem cell , medicine , disease , regeneration (biology) , intensive care medicine , cell , cardiac cell , clinical trial , bioinformatics , mesenchymal stem cell , pathology , biology , microbiology and biotechnology , genetics
Stem cell therapy is a promising strategy for tissue regeneration. The therapeutic benefits of cell therapy are mediated by both direct and indirect mechanisms. However, the application of stem cell therapy in the clinic is hampered by several limitations. This concise review provides a brief introduction into stem cell therapies for ischemic heart disease. It summarizes cell‐based and cell‐free paradigms, their limitations, and the benefits of using them to target disease. Stem Cells Translational Medicine 2018;7:354–359